Clinical Trial Update: The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating whether renin-angiotensin system blockade, a calcium channel blocker, or their combination affect TWEAK, PTX3, and flow-mediat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Hypertension
• Proteinuria

Drugs mentioned

• Calcium channel blocker (calcium channel blocker)
• Combined therapy: RAS blocker + Calcium channel blocker (Combination therapy)
• Renin-angiotensin system blocker (RAS blocker)

Snippet

Sponsor: Gulhane School of Medicine | Conditions: Diabetes, Hypertension | Phase 4 | Status: COMPLETED